QRG Capital Management Inc. Trims Position in Cencora, Inc. $COR

QRG Capital Management Inc. lowered its position in Cencora, Inc. (NYSE:COR) by 43.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,632 shares of the company’s stock after selling 9,014 shares during the quarter. QRG Capital Management Inc.’s holdings in Cencora were worth $3,635,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of COR. Atlantic Edge Private Wealth Management LLC increased its holdings in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC grew its position in Cencora by 69.4% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after acquiring an additional 43 shares during the period. Caldwell Trust Co acquired a new stake in Cencora during the second quarter worth $46,000. Salomon & Ludwin LLC raised its position in Cencora by 638.1% in the third quarter. Salomon & Ludwin LLC now owns 155 shares of the company’s stock valued at $47,000 after purchasing an additional 134 shares during the period. Finally, Capital A Wealth Management LLC lifted its stake in shares of Cencora by 3,975.0% in the 2nd quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock valued at $49,000 after purchasing an additional 159 shares during the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $343.45, for a total value of $1,750,221.20. Following the sale, the chief executive officer owned 68,059 shares of the company’s stock, valued at $23,374,863.55. This trade represents a 6.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 15,220 shares of company stock worth $5,343,561. Company insiders own 10.80% of the company’s stock.

Cencora Stock Down 0.1%

Cencora stock opened at $354.96 on Monday. Cencora, Inc. has a twelve month low of $237.71 and a twelve month high of $377.54. The stock’s fifty day simple moving average is $349.64 and its 200-day simple moving average is $320.32. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The firm has a market capitalization of $68.86 billion, a P/E ratio of 44.65, a P/E/G ratio of 1.69 and a beta of 0.66.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period last year, the business posted $3.34 earnings per share. Cencora’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This is a positive change from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is currently 30.19%.

Analysts Set New Price Targets

COR has been the subject of a number of recent analyst reports. UBS Group raised their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Robert W. Baird set a $415.00 price target on shares of Cencora in a research report on Tuesday, January 13th. Weiss Ratings reissued a “hold (c+)” rating on shares of Cencora in a research note on Monday, December 29th. Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Finally, TD Cowen lifted their target price on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $381.42.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.